Literature DB >> 29115915

Neuromodulation in multiple sclerosis.

Hesham Abboud1, Eddie Hill2, Junaid Siddiqui3, Alessandro Serra4, Benjamin Walter5.   

Abstract

Neuromodulation, or the utilization of advanced technology for targeted electrical or chemical neuronal stimulation or inhibition, has been expanding in several neurological subspecialties. In the past decades, immune-modulating therapy has been the main focus of multiple sclerosis (MS) research with little attention to neuromodulation. However, with the recent advances in disease-modifying therapies, it is time to shift the focus of MS research to neuromodulation and restoration of function as with other neurological subspecialties. Preliminary research supports the value of intrathecal baclofen pump and functional electrical stimulation in improving spasticity and motor function in MS patients. Deep brain stimulation can improve MS-related tremor and trigeminal neuralgia. Spinal cord stimulation has been shown to be effective against MS-related pain and bladder dysfunction. Bladder overactivity also responds to sacral neuromodulation and posterior tibial nerve stimulation. Despite limited data in MS, transcranial magnetic stimulation and brain-computer interface are promising neuromodulatory techniques for symptom mitigation and neurorehabilitation of MS patients. In this review, we provide an overview of the available neuromodulatory techniques and the evidence for their use in MS.

Entities:  

Keywords:  BCI; DBS; FES; Neuromodulation; baclofen pump; multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29115915     DOI: 10.1177/1352458517736150

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  Neuronal activity in vivo enhances functional myelin repair.

Authors:  Fernando C Ortiz; Chloé Habermacher; Mariana Graciarena; Pierre-Yves Houry; Akiko Nishiyama; Brahim Nait Oumesmar; María Cecilia Angulo
Journal:  JCI Insight       Date:  2019-03-21

Review 2.  Supraspinal Mechanisms of Spinal Cord Stimulation for Modulation of Pain: Five Decades of Research and Prospects for the Future.

Authors:  Eellan Sivanesan; Dermot P Maher; Srinivasa N Raja; Bengt Linderoth; Yun Guan
Journal:  Anesthesiology       Date:  2019-04       Impact factor: 7.892

Review 3.  Invasive Therapies in Multiple Sclerosis.

Authors:  Cihat Uzunköprü
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

Review 4.  Can Operant Conditioning of EMG-Evoked Responses Help to Target Corticospinal Plasticity for Improving Motor Function in People With Multiple Sclerosis?

Authors:  Aiko K Thompson; Thomas Sinkjær
Journal:  Front Neurol       Date:  2020-07-15       Impact factor: 4.003

Review 5.  Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders.

Authors:  Ryuji Sakakibara
Journal:  Clin Auton Res       Date:  2018-08-03       Impact factor: 4.435

6.  Movement disorders in early MS and related diseases: A prospective observational study.

Authors:  Hesham Abboud; Xin Xin Yu; Konrad Knusel; Hubert H Fernandez; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2019-02

7.  Functional brain imaging in voiding dysfunction.

Authors:  Rose Khavari; Timothy B Boone
Journal:  Curr Bladder Dysfunct Rep       Date:  2019-02-08

Review 8.  Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis.

Authors:  Joanna Saluk-Bijak; Angela Dziedzic; Michal Bijak
Journal:  Cells       Date:  2019-02-01       Impact factor: 6.600

Review 9.  Therapeutic Approaches for Peripheral and Central Neuropathic Pain.

Authors:  Délia Szok; János Tajti; Aliz Nyári; László Vécsei
Journal:  Behav Neurol       Date:  2019-11-21       Impact factor: 3.342

10.  Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review.

Authors:  Chiara Zucchella; Elisa Mantovani; Roberto De Icco; Cristina Tassorelli; Giorgio Sandrini; Stefano Tamburin
Journal:  Front Neurosci       Date:  2020-11-20       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.